COVID-19 Burden on HIV Patients Attending Antiretroviral Therapy in Addis Ababa, Ethiopia: A Multicenter Cross-Sectional Study
Related Experiment Video
Updated: Sep 29, 2025

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Dagmawi Chilot1,2, Yimtubezinash Woldeamanuel1, Tsegahun Manyazewal1
1Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Insights
The COVID-19 pandemic significantly disrupted HIV care in Ethiopia, leading to missed appointments for medication refills and follow-ups. Fear of COVID-19, transport issues, and reduced income were key barriers for patients on antiretroviral therapy.
Area of Science:
- Public Health
- Infectious Diseases
- HIV/AIDS Management
Background:
- Ethiopia has made progress in HIV screening, testing, and retention.
- Concerns exist about COVID-19 disrupting HIV programs, potentially increasing mortality and new infections.
- This study investigated the impact of COVID-19 on patients receiving antiretroviral therapy (ART).
Purpose of the Study:
- To assess the real-time burden of COVID-19 on HIV-positive patients undergoing antiretroviral therapy.
- To identify factors contributing to missed appointments and follow-up services during the pandemic.
Main Methods:
- A multicenter, cross-sectional study was conducted in 10 healthcare facilities in Addis Ababa, Ethiopia.
- Data were collected from 212 HIV-positive patients using interviewer-based questionnaires.
- Statistical analysis was performed using SPSS version 26.
Main Results:
- 27.4% of patients missed medication refill appointments, with predictors including age ≥ 55, fear of COVID-19, transport disruption, reduced income, and limited access to masks.
- 26.4% missed diagnostic tests, influenced by age, partial lockdown, limited health service access, reduced income, and mask availability.
- 25.9% missed counseling services, with significant predictors being age ≥ 55, fear of COVID-19, reduced income, mask availability, and partial lockdown.
Conclusions:
- COVID-19 significantly burdened HIV patients' ability to attend routine clinical care and treatment.
- Missed appointments for refills, clinical, and laboratory follow-ups may lead to treatment failure and drug resistance.
- Targeted initiatives are crucial to sustain HIV care and improve the well-being of people living with HIV.
Background:
There has been promising progress toward screening, testing, and retaining patients with HIV in care in Ethiopia. Concern exists that possible disruptions in HIV programs due to coronavirus disease 2019 (COVID-19) could result in a more HIV-related mortality and new HIV infections. This study aimed to investigate the real-time burden of COVID-19 on patients with HIV attending antiretroviral therapy.
Methods:
We conducted a facility-based, multicenter, and cross-sectional study among patients with HIV attending antiretroviral therapy in 10 healthcare facilities in Addis Ababa, Ethiopia, in the COVID-19 pandemic period. Data were collected using adapted, interviewer-based questionnaires, and entered into EpiInfo version 7 and exported to SPSS version 26 for analysis.
Result:
A total of 212 patients with HIV were included. The participants who missed visits for refill were 58 (27.4%). When the effects of other independent variables on appointments/visits for refill were controlled, the following characteristics were found to be the most important predictors of missed appointments (p< 0.05): age ≥ 55 [adjusted odds ratio (AOR) = 6.73, 95% CI (1.495-30.310)], fear of COVID-19 [AOR = 24.93, 95% CI (2.798-222.279)], transport disruption [AOR = 4.90, 95% CI (1.031-23.174)], reduced income for traveling to a health facility [AOR = 5.64, 95% CI (1.234-25.812)], limited access to masks [AOR = 7.67, 95% CI (1.303-45.174)], sanitizer [AOR = 0.07, 95% CI (0.007-0.729)], and non-medical support [AOR = 2.32, 95% CI (1.547-12.596)]. The participants were well aware of the COVID-19 preventive measures. The most costly COVID-19 preventive measures that cause financial burden to the patients were the costs for buying face masks (63.7%), disinfectants (55.2%), and soap for handwashing (22.2%). The participants who missed follow-up diagnostic tests were 56 (26.4%). Variables, which were found to be statistically significant, include the following: age ≥ 55 [AOR = 0.22, 95% CI (0.076-0.621)], partial lockdown [AOR = 0.10, 95% CI (0.011-0.833)], limited access to health services [AOR = 0.15, 95% CI (0.045-0.475)], reduced income for traveling to health facility [AOR = 0.18, 95% CI (0.039-0.784)], and unable to get masks [AOR = 0.12, 95% CI (0.026-0.543)]. The participants who missed counseling services were 55 (25.9%). In multivariate logistic regression, the following were statistically significant: age ≥ 55 [AOR = 0.21, 95% CI (0.078-0.570)], fear of COVID-19 [AOR = 0.11, 95% CI (0.013-0.912)], reduced income [AOR = 0.17, 95% CI (0.041-0.699)], unable to get face masks [AOR = 0.19, 95% CI (0.039-0.959)], and partial lockdown [AOR = 0.08, 95% CI (0.008-0.790)].
Conclusions:
The COVID-19 had a significant burden on patients with HIV to attend their routine clinical care and treatment, which may lead to treatment failure and drug resistance. The impact was on their appointments for medication refills and clinical and laboratory follow-ups. Targeted initiatives are needed to sustain HIV clinical care and treatment services and improve the well-being of people living with HIV.
More Related Videos
23:56Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
13:58Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
Published on: September 26, 2011
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Retrovirus Life Cycles
Sexually Transmitted Infections
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...